Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Min Zhao, Irmela Mantel, Emmanuelle Gelize, Xinxin Li, Xiaoyue Xie, Alejandro Arboleda, Marie Seminel, Rinath Levy-Boukris, Marilyn Dernigoghossian, Andrea Prunotto, Charlotte Andrieu-Soler, Carlo Rivolta, Jérémie Canonica, Marie-Christine Naud, Sebastian Lechner, Nicolette Farman, Irene Bravo-Osuna, Rocio Herrero-Vanrell, Frederic Jaisser, Francine Behar-Cohen, Min Zhao, Irmela Mantel, Emmanuelle Gelize, Xinxin Li, Xiaoyue Xie, Alejandro Arboleda, Marie Seminel, Rinath Levy-Boukris, Marilyn Dernigoghossian, Andrea Prunotto, Charlotte Andrieu-Soler, Carlo Rivolta, Jérémie Canonica, Marie-Christine Naud, Sebastian Lechner, Nicolette Farman, Irene Bravo-Osuna, Rocio Herrero-Vanrell, Frederic Jaisser, Francine Behar-Cohen
Abstract
Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory to intraocular anti-VEGF injections. Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition of the MR pathway or endothelial-specific deletion of MR inhibits CNV through VEGF-independent mechanisms, in part through upregulation of the extracellular matrix protein decorin. Intravitreal injections of spironolactone-loaded microspheres and systemic delivery lead to similar reductions in CNV. Together, our work suggests MR inhibition as a novel therapeutic option for wet AMD patients unresponsive to anti-VEGF drugs.
Conflict of interest statement
M.Z. and F.B.-C. are listed as inventors in a patent application related to the “Methods and pharmaceutical compositions for the treatment of choroidal neovascularization” (WO2017064121A1, https://patents.google.com/patent/WO2017064121A1/en). The remaining authors declare no competing interests.
Figures
References
- Wong, W. al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2, e106–e116 (2014).
- Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147–1159. doi: 10.1016/S0140-6736(18)31550-2.
- Kaneko H, et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011;471:325–330. doi: 10.1038/nature09830.
- Celkova L, Doyle SL, Campbell M . NLRP3 inflammasome and pathobiology in AMD. J. Clin. Med. 2015;4:172–192. doi: 10.3390/jcm4010172.
- Whitmore SS, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog. Retin. Eye Res. 2015;45:1–29. doi: 10.1016/j.preteyeres.2014.11.005.
- Witmer AN, Vrensen GFJM, Van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 2003;22:1–29. doi: 10.1016/S1350-9462(02)00043-5.
- Bhutto I, Lutty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol. Asp. Med. 2012;33:295–317. doi: 10.1016/j.mam.2012.04.005.
- Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog. Retin. Eye Res. 2015;49:67–81. doi: 10.1016/j.preteyeres.2015.06.002.
- Zhang SX, Ma J. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog. Retin. Eye Res. 2007;26:1–37. doi: 10.1016/j.preteyeres.2006.09.002.
- Ba J, et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Des. Devel. Ther. 2015;9:5397–5405.
- Rezar-Dreindl S, et al. The intraocular cytokine profile and therapeutic response in persistent neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2016;57:4144–4150. doi: 10.1167/iovs.16-19772.
- Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–1761. doi: 10.1016/j.ophtha.2016.03.045.
- Rush RB, Rush SW, Aragon AV, Ysasaga JE. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy. Am. J. Ophthalmol. 2014;158:337–344. doi: 10.1016/j.ajo.2014.05.007.
- Framme C, Panagakis G, Birngruber R. Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 2010;51:1671–1676. doi: 10.1167/iovs.09-4496.
- Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des. Devel. Ther. 2016;10:1857–1867. doi: 10.2147/DDDT.S115121.
- Miller JW. Beyond VEGF-the weisenfeld lecture. Invest. Ophthalmol. Vis. Sci. 2016;57:6911–6918. doi: 10.1167/iovs.16-21201.
- Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration–a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31. doi: 10.1186/s12886-016-0207-3.
- CATT Research Group, .et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897–1908 (2011).
- Gewaily, D., Muthuswamy, K. & Greenberg, P. B. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst. Rev. CD007324 (2015). 10.1002/14651858.CD007324.pub3
- Cao JH, Mulvahill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. 2014;121:1871–1876. doi: 10.1016/j.ophtha.2014.04.012.
- Whitcup SM, Cidlowski JA, Csaky KG, Ambati J. Pharmacology of corticosteroids for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2018;59:1–12. doi: 10.1167/iovs.17-22259.
- Zhao M, et al. The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. Faseb J. 2010;24:3405–3415. doi: 10.1096/fj.09-154344.
- Zhao M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J. Clin. Invest. 2012;122:2672–2679. doi: 10.1172/JCI61427.
- Daruich A, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 2015;48:82–118. doi: 10.1016/j.preteyeres.2015.05.003.
- Daruich A, et al. Oral mineralocorticoid-receptor antagonists: Real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl. Vis. Sci. Technol. 2016;5:2. doi: 10.1167/tvst.5.2.2.
- Bousquet E, et al. Spironolactone for nonresolving central serous chorioretinopathy: A randomized controlled crossover study. Retina. 2015;35:2505–2515. doi: 10.1097/IAE.0000000000000614.
- Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. Pharmacol. Rev. 2016;68:49–75. doi: 10.1124/pr.115.011106.
- Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375–1378. doi: 10.1126/science.2416056.
- Fujii M, et al. Aldosterone inhibits endothelial morphogenesis and angiogenesis through the downregulation of vascular endothelial growth factor receptor-2 expression subsequent to peroxisome proliferator-activated receptor gamma. J. Steroid Biochem. Mol. Biol. 2012;129:145–152. doi: 10.1016/j.jsbmb.2011.12.014.
- Michel F, et al. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004;109:1933–1937. doi: 10.1161/01.CIR.0000127112.36796.9B.
- Miternique-Grosse A, et al. Antiangiogenic effects of spironolactone and other potassium-sparing diuretics in human umbilical vein endothelial cells and in fibrin gel chambers implanted in rats. J. Hypertens. 2006;24:2207–2213. doi: 10.1097/01.hjh.0000249698.26983.4e.
- Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ. Res. 2009;104:124–133. doi: 10.1161/CIRCRESAHA.108.176008.
- Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 2010;29:500–519. doi: 10.1016/j.preteyeres.2010.05.003.
- Kolkhof P, Bärfacker L. 30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 2017;234:T125–T140. doi: 10.1530/JOE-16-0600.
- Zhao M, et al. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. J. Control. Release. 2017;266:187–197. doi: 10.1016/j.jconrel.2017.09.029.
- Schäfer N, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur. Heart J. 2013;34:3515–3524. doi: 10.1093/eurheartj/eht095.
- Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120:106–114. doi: 10.1016/j.ophtha.2012.07.038.
- Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology. 2004;111:250–255. doi: 10.1016/j.ophtha.2003.05.030.
- Jung JJ, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am. J. Ophthalmol. 2014;158:769–779.e2. doi: 10.1016/j.ajo.2014.07.006.
- Heier JS, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi: 10.1016/j.ophtha.2012.09.006.
- Hussain RM, Ciulla TA. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Exp. Opin. Emerg. Drugs. 2017;22:235–246. doi: 10.1080/14728214.2017.1362390.
- Kapoor KG, Todi N, Wagner AL. Mineralocorticoid antagonists as adjuncts in neovascular age-related macular degeneration. Ophthalmol. Ther. 2017;6:141–146. doi: 10.1007/s40123-016-0075-1.
- Grunin M, Hagbi-Levi S, Chowers I. The role of monocytes and macrophages in age-related macular degeneration. Adv. Exp. Med. Biol. 2014;801:199–205. doi: 10.1007/978-1-4614-3209-8_26.
- Combadière C, et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J. Clin. Invest. 2007;117:2920–2928. doi: 10.1172/JCI31692.
- Usher MG, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010;120:3350–3364. doi: 10.1172/JCI41080.
- Barrera-Chimal J, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93:1344–1355. doi: 10.1016/j.kint.2017.12.016.
- Järveläinen H, Sainio A, Wight TN. Pivotal role for decorin in angiogenesis. Matrix Biol. 2015;43:15–26. doi: 10.1016/j.matbio.2015.01.023.
- Frikeche J, Maiti G, Chakravarti S. Small leucine-rich repeat proteoglycans in corneal inflammation and wound healing. Exp. Eye Res. 2016;151:142–149. doi: 10.1016/j.exer.2016.08.015.
- Keenan TDL, et al. Mapping the differential distribution of proteoglycan core proteins in the adult human retina, choroid, and sclera. Invest. Ophthalmol. Vis. Sci. 2012;53:7528–7538. doi: 10.1167/iovs.12-10797.
- Gubbiotti MA, Vallet SD, Ricard-Blum S, Iozzo RV. Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions. Matrix Biol. 2016;55:7–21. doi: 10.1016/j.matbio.2016.09.009.
- Nelimarkka L, et al. Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am. J. Pathol. 2001;158:345–353. doi: 10.1016/S0002-9440(10)63975-2.
- Schönherr E, et al. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J. Vasc. Res. 2004;41:499–508. doi: 10.1159/000081806.
- Neill T, Schaefer L, Iozzo RV. Decorin as a multivalent therapeutic agent against cancer. Adv. Drug Deliv. Rev. 2016;97:174–185. doi: 10.1016/j.addr.2015.10.016.
- Neill T, et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012;287:5492–5506. doi: 10.1074/jbc.M111.283499.
- Du S, Wang S, Wu Q, Hu J, Li T. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells. Exp. Eye Res. 2013;116:151–160. doi: 10.1016/j.exer.2013.08.019.
- Xaus J, Comalada M, Cardó M, Valledor AF, Celada A. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1) Blood. 2001;98:2124–2133. doi: 10.1182/blood.V98.7.2124.
- Mohan RR, et al. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS ONE. 2011;6:e26432. doi: 10.1371/journal.pone.0026432.
- Wang X, et al. TGF-β participates choroid neovascularization through Smad2/3-VEGF/TNF-α signaling in mice with Laser-induced wet age-related macular degeneration. Sci. Rep. 2017;7:9672. doi: 10.1038/s41598-017-10124-4.
- Yuan X, et al. Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell. Proteom. 2010;9:1031–1046. doi: 10.1074/mcp.M900523-MCP200.
- Gergely R, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: A comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37:1084–1091. doi: 10.1097/IAE.0000000000001303.
- Funder J. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor activation and specificity-conferring mechanisms: a brief history. J. Endocrinol. 2017;234:T17–T21. doi: 10.1530/JOE-17-0119.
- Barrera-Chimal J, et al. Benefit of mineralocorticoid receptor antagonism in AKI: Role of vascular smooth muscle Rac1. J. Am. Soc. Nephrol. 2017;28:1216–1226. doi: 10.1681/ASN.2016040477.
- Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic. Res. 1999;8:265–277. doi: 10.1023/A:1008942828960.
- Mueller KB, et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension. 2015;66:988–997. doi: 10.1161/HYPERTENSIONAHA.115.06172.
- Fraccarollo D, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation. 2011;123:400–408. doi: 10.1161/CIRCULATIONAHA.110.983023.
- Wang Y, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010;465:483–486. doi: 10.1038/nature09002.
- Wendling O, Bornert JM, Chambon P, Metzger D. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis. 2009;47:14–18. doi: 10.1002/dvg.20448.
Source: PubMed